The global incidence of malignant lymphoma, which originates in the lymphatic reticular tissue, shows significant regional differences. In China, its incidence is about half that of Western countries and only about one-third of that of Japan, ranking 11th to 13th among all malignant tumors. However, in recent years, there has been an upward trend in its incidence. The disease mostly affects young and middle-aged people, with a sex ratio of about 3:1, and about 5% to 6% of cases have a family history.
Lymphoma can be divided into two main categories: Hodgkin lymphoma and non-Hodgkin lymphoma. There is no specific name for malignant lymphoma in traditional Chinese medicine, but depending on the symptoms of swollen lymph nodes, it may be called "scrofula", "loss of honor", "lithorcus", "malignant nucleus", etc. The common characteristics of these diseases are that the color does not change, and it is not painful or itchy, which belongs to the category of "yin" in traditional Chinese medicine.
The exact cause of lymphoma is unknown, but researchers believe that viral infection, physicochemical factors, immunodeficiency, and chromosomal abnormalities may be key factors in the disease. For example, Epstein-Barr virus antibodies in African lymphoma patients are often markedly elevated, and viral particles can be detected in tumor tissue even under electron microscopy. Long-term exposure to certain physical and chemical factors, such as Hiroshima atomic bomb survivors, may also increase the risk of lymphoma. Patients with immunodeficiency conditions, such as systemic lupus erythematosus and Sjögren's syndrome, are at increased risk of comorbidity with lymphoma, and patients with AIDS also have a higher incidence of lymphoma. In addition, certain chromosomal abnormalities such as t(8; 14) Translocation, which may also lead to tumor deterioration.
*The survival period after depends on the type of lymphoma and the clinical stage. The five-year survival rate for patients with Hodgkin lymphoma after receiving chemoradiotherapy is about 805%。Survival in patients with non-Hodgkin lymphoma varies depending on the degree of malignancy of the tumor, with a median survival of about 5 for low-grade malignancy1 to 72 years, moderately malignant is 15 to 34 years, and only 0 for high malignancy7 to 20 years. Patients with early detection and ** generally have a better prognosis, while children and older adults have a relatively poor prognosis. In addition, improved methods and improved quality of life also contribute to improved patient survival. Although malignant lymphoma is a serious disease, advances in science and technology and improvements in medical conditions have brought new hope to patients.